GALVESTON, Texas--(BUSINESS WIRE)--Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the American Thoracic Society Meeting in San Diego.
The Respiratory Innovation Summit (RIS) has been established by the American Thoracic Society to unite innovators, investors, clinicians, and advocacy groups to help create powerful new treatments for deadly and crippling diseases of the lungs and airways. Each year, companies developing respiratory devices and therapeutics are invited to submit abstracts describing how their innovative therapies may change the treatment of lung disease.
This year, Chrysalis was selected as one of six “Critical Care Therapeutic Innovator” companies for oral presentation at the Summit.
“To be selected to present at the Respiratory Summit is a great honor for Chrysalis and confirms that experts in this field recognize the potential of TP508 (Chrysalin™) to prevent progression of acute lung injury,” said Dr. Darrell Carney, Chrysalis CEO.
Chrysalis is developing TP508, a natural thrombin-derived peptide, to treat Acute Respiratory Distress Syndrome (ARDS) which affects over a million people each year with up to 35 percent dying within weeks of diagnosis. Of those who survive, most experience decreased lung function or progressive fibrosis.
“Based on preclinical results with COVID and acute lung injury models, we expect TP508 to stop the progression of ARDS,” said Dr. Laurie Sower, Chrysalis EVP.
Chrysalis has received FDA IND approval to proceed into human clinical trials and has initiated a Phase 1 Safety/PK trial, with subsequent trials in ARDS patients to follow as the company receives funding for these trials.
Chrysalis BioTherapeutics, Inc. is a privately held Galveston, TX-based biopharmaceutical company with world-wide license to the TP508 technology from the University of Texas System and the University of Texas Medical Branch (UTMB). Chrysalis BioTherapeutics is currently seeking investors and pharma partners for pulmonary and other indications including TBI, radiation therapy and mitigation chronic pulmonary diseases. Chrysalin™ drug development programs have been funded by NIH and the Biomedical Advanced Research and Development Authority (BARDA) both part of the U.S. Department of Health and Human Services. For more information contact dcarney@chrysbio.com or visit www.chrysbio.com.
